Key result
Damaging MYH6 variants strongly associate with HLHS and predict reduced transplant-free survival.
Why the study?
Are damaging MYH6 variants enriched in patients with hypoplastic left heart syndrome and do they affect clinical outcomes?
Case-Control (n=190)
Are damaging MYH6 variants enriched in patients with hypoplastic left heart syndrome and do they affect clinical outcomes?
Rare, damaging variants in the MYH6 gene are enriched in patients with hypoplastic left heart syndrome and are predictive of poorer transplant-free survival.
Answers are grounded in this paper and cite their sources.
MYH6 variants may identify higher-risk HLHS patients; leaves open whether screening or targeted interventions improve outcomes.
Hypoplastic left heart syndrome (HLHS) is a clinically and anatomically severe form of congenital heart disease (CHD). Although prior studies suggest that HLHS has a complex genetic inheritance, its etiology remains largely unknown. The goal of this study was to characterize a risk gene in HLHS and its effect on HLHS etiology and outcome. We performed next-generation sequencing on a multigenerational family with a high prevalence of CHD/HLHS, identifying a rare variant in the α-myosin heavy chain ( MYH6) gene. A case-control study of 190 unrelated HLHS subjects was then performed and compared with the 1000 Genomes Project. Damaging MYH6 variants, including novel, missense, in-frame deletion, premature stop, de novo, and compound heterozygous variants, were significantly enriched in HLHS cases ( P < 1 × 10 −5 ). Clinical outcomes analysis showed reduced transplant-free survival in HLHS subjects with damaging MYH6 variants ( P < 1 × 10 −2 ). Transcriptome and protein expression analyses with cardiac tissue revealed differential expression of cardiac contractility genes, notably upregulation of the β-myosin heavy chain ( MYH7) gene in subjects with MYH6 variants ( P < 1 × 10 −3 ). We subsequently used patient-specific induced pluripotent stem cells (iPSCs) to model HLHS in vitro. Early stages of in vitro cardiomyogenesis in iPSCs derived from two unrelated HLHS families mimicked the increased expression of MYH7 observed in vivo ( P < 1 × 10 −2 ), while revealing defective cardiomyogenic differentiation. Rare, damaging variants in MYH6 are enriched in HLHS, affect molecular expression of contractility genes, and are predictive of poor outcome. These findings indicate that the etiology of MYH6-associated HLHS can be informed using iPSCs and suggest utility in future clinical applications.
No takes yet. Share an insight, caveat, or question.
Tomita‐Mitchell et al. (2016) conducted a case-control in Hypoplastic left heart syndrome (HLHS) (n=190). Damaging MYH6 variants vs. 1000 Genomes Project was evaluated on Enrichment of damaging MYH6 variants (p=< 1 × 10^-5). Damaging MYH6 variants were enriched in HLHS cases compared to controls and predicted reduced transplant-free survival.
Synapse has enriched 10 related papers. Consider them for comparative context: